Expand TELO Menu
TELO MENU

TELO Latest Press Releases

-- January 5, 2026 --

Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models ACCESS Newswire 8:00 AM

-- December 18, 2025 --

Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development ACCESS Newswire 7:30 AM

-- November 25, 2025 --

Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells ACCESS Newswire 8:00 AM

-- November 21, 2025 --

Telomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells ACCESS Newswire 7:30 AM

-- November 12, 2025 --

Telomir Pharmaceuticals Reports Telomir-1 Outperforms FDA-Approved Gold-Standard Iron Chelator Deferoxamine (DFO) in Reducing Intracellular Iron in a Human Cell Line ACCESS Newswire 8:00 AM

-- October 23, 2025 --

Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Resets Cancer's "Kill-and-Clean" Defense Systems in an Aggressive Prostate Cancer Model, Outperforming Rapamycin and Chemo ACCESS Newswire 7:30 AM

-- October 21, 2025 --

Telomir Pharmaceuticals Executes Binding LOI for Worldwide Rights to Telomir-1, Positioning the Company for Global Market Expansion and Value Growth ACCESS Newswire 7:30 AM

-- October 14, 2025 --

Telomir Pharmaceuticals Announces New Data Showing That Telomir-1 Kills Aggressive Pancreatic Cancer Cells, One of the Deadliest Forms of Cancer ACCESS Newswire 8:05 AM

-- October 9, 2025 --

Telomir Pharmaceuticals Reports Discovery That Telomir-1 Selectively Kills Aggressive Triple-Negative Breast Cancer Cells ACCESS Newswire 7:30 AM

-- October 7, 2025 --

Telomir Pharmaceuticals Announces New Findings in a Prostate Cancer Model Demonstrating Telomir-1 Also Resets DNA Methylation of Tumor Suppressor Genes Implicated in Two of the Most Persistent Challenges in Oncology-Metastasis and Treatment Resistance ACCESS Newswire 7:30 AM

-- September 18, 2025 --

Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Targets Additional Histone Demethylase Families, a Unique Profile in Cancer and Aging Not Seen in Other Therapies ACCESS Newswire 8:00 AM

-- September 9, 2025 --

Telomir Pharmaceuticals Announces New Cancer Data in Aggressive Human Prostate Cancer Cells Showing Telomir-1 Resets DNA Methylation to Reactivate CDKN2A, a Master Tumor Suppressor, Outperforming Rapamycin and Chemotherapy ACCESS Newswire 8:12 AM
Market Data Delayed 15 Minutes